3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Hepatocellular
28
Carcinoma, Non-Small-Cell Lung
11
Liver Neoplasms
7
Lung Neoplasms
5
Urinary Bladder Neoplasms
4
Small Cell Lung Carcinoma
4
Diabetes Mellitus, Insulin-Dependent, 12
4
Pancreatic Neoplasms
3
Neoplasms
3
Colorectal Neoplasms
3
Cholangiocarcinoma
3
Biliary Tract Neoplasms
3
Adenocarcinoma Of Esophagus
3
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Mesothelioma
2
Fallopian Tube Neoplasms
2
Carcinoma
2
Urothelial Cancer
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Unresectable Hepatocellular Carcinoma
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Malignancies
1
Seminoma
1
Rare Diseases
1
Interventions
durvalumab
2
tremelimumab
1
ceralasertib
1
aflutinib
1
Radiotherapy
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non Small Cell Lung Cancer NSCLC
×
tremelimumab
×
1 year
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA